阿奇霉素治疗支原体肺炎患儿的临床效果分析
|
摘要
目的探究阿奇霉素治疗支原体肺炎患儿的有效性及不良反应。方法选取我院2015年3月—2017年9月收治的支原体肺炎患儿68例,其中接受红霉素治疗的34例患儿为对照组,接受阿奇霉素治疗的34例患儿为观察组,比较两组的住院时间、退热时间、啰音消失时间、咳嗽缓解时间、临床疗效以及不良反应发生率。结果观察组退热时间(3.07±0.95)d、咳嗽缓解时间(4.14±1.29)d、啰音消失时间(4.37±1.41)d以及住院时间(7.24±2.37)d,均短于对照组[(4.21±1.04)d、(5.35±1.58)d、(6.52±1.84)d、(9.85±3.12)d],两组差异有统计学意义(P <0.05);对照组不良反应发生率为26.47%(9/34),其分别为胃肠道反应5例、皮疹2例和静脉刺激2例,观察组不良反应发生率为5.88%(2/34),胃肠道反应和静脉刺激各1例,两组差异有统计学意义(P <0.05)。在临床总有效率上,组间差异无统计学意义(P> 0.05)。结论阿奇霉素在支原体肺炎患儿中应用效果良好,能够有效缩短患儿症状缓解时间和住院时间,且安全性可靠。
Objective To explore the efficacy and adverse reactions of azithromycin in the treatment of children with Mycoplasma pneumonia.Methods 68 children with mycoplasma pneumonia admitted to our hospital from March 2015 to September 2017 were selected, of which 34 children received erythromycin as control group and 34 children received azithromycin as observation group. The hospitalization time, antipyretic time, rale disappearance time, cough relief time, clinical efficacy and adverse reactions were compared between the two groups. Results The antipyretic time(3.07±0.95) d, cough remission time(4.14±1.29)d, rale disappearance time(4.37±1.41) d and hospitalization time(7.24±2.37)d in the observation group were lower than those in the control group[(4.21±1.04)d,(5.35±1.58)d,(6.52±1.84)d,(9.85±3.12)d], respectively.The difference was statistically significant(P < 0.05). The incidence of adverse reactions was 26.47%(9/34), including gastrointestinal reactions in 5 cases, rashes in 2 cases and intravenous stimulation in 2 cases. The incidence of adverse reactions in the observation group was5.88%(2/34), which was 1 case for gastrointestinal reactions and 1 case for intravenous stimulation respectively. The data were statistically significant(P < 0.05). And there was no significant difference in the total clinical effective rate(P > 0.05). Conclusion Azithromycin has good effect in children with Mycoplasma pneumonia. It can effectively shorten the remission time and hospitalization time of children with Mycoplasma pneumonia, and is safe and reliable.
Objective To explore the efficacy and adverse reactions of azithromycin in the treatment of children with Mycoplasma pneumonia.Methods 68 children with mycoplasma pneumonia admitted to our hospital from March 2015 to September 2017 were selected, of which 34 children received erythromycin as control group and 34 children received azithromycin as observation group. The hospitalization time, antipyretic time, rale disappearance time, cough relief time, clinical efficacy and adverse reactions were compared between the two groups. Results The antipyretic time(3.07±0.95) d, cough remission time(4.14±1.29)d, rale disappearance time(4.37±1.41) d and hospitalization time(7.24±2.37)d in the observation group were lower than those in the control group[(4.21±1.04)d,(5.35±1.58)d,(6.52±1.84)d,(9.85±3.12)d], respectively.The difference was statistically significant(P < 0.05). The incidence of adverse reactions was 26.47%(9/34), including gastrointestinal reactions in 5 cases, rashes in 2 cases and intravenous stimulation in 2 cases. The incidence of adverse reactions in the observation group was5.88%(2/34), which was 1 case for gastrointestinal reactions and 1 case for intravenous stimulation respectively. The data were statistically significant(P < 0.05). And there was no significant difference in the total clinical effective rate(P > 0.05). Conclusion Azithromycin has good effect in children with Mycoplasma pneumonia. It can effectively shorten the remission time and hospitalization time of children with Mycoplasma pneumonia, and is safe and reliable.
引文
[1]梁锦枝,吴锗珊,罗钦宏,等.喜炎平联合阿奇霉素治疗支原体肺炎疗效的Meta分析[J].中国实验方剂学杂志,2014,20(18):220-224.
[2]陈会新,宋爱丽,肖永红.痰热清联合阿奇霉素治疗支原体肺炎疗效观察[J].临床肺科杂志,2014,19(2):359-361.
[3]王文雅,张秀敏,杜会双,等.阿奇霉素对支原体肺炎患儿血清IgA、IgG、IgM水平及T淋巴细胞亚群的影响[J].蚌埠医学院学报,2016,41(2):175-177.
[4]王宋青,施益农.热毒宁联合阿奇霉素对支原体肺炎患儿炎性因子及临床疗效的影响[J].广西医学,2016,38(8):1078-1080.
[5]陈跃宣,马洪梅.热毒宁联合阿奇霉素对支原体肺炎患儿抗炎、促炎因子及免疫功能的影响[J].海南医学院学报,2014,20(12):1702-1704.
[6]朴峻.痰热清注射液联合阿奇霉素对支原体肺炎患者肺功能、血清及痰液炎症介质的影响研究[J].世界中西医结合杂志,2016,11(3):388-391.
[7]夏玉平,方圆.孟鲁司特钠联合阿奇霉素对支原体肺炎儿童免疫功能及肺功能的影响[J].海南医学院学报,2016,22(18):2115-2117,2121.
[8]梁静仪,卢绍佳,姚春松,等.阿奇霉素对支原体肺炎患儿血清IL-2、sIL-2R及IL-17水平的影响[J].国际检验医学杂志,2014,35(8):956-957.
[9]谭义林,叶池林.布地奈德雾化吸入联合阿奇霉素对支原体肺炎患儿肺功能及血清炎症因子、免疫功能的影响[J].海南医学院学报,2016,22(22):2782-2784.
[10]宋海燕,王彬.红霉素与阿奇霉素治疗支原体肺炎临床效果比较[J].中国基层医药,2016,23(19):3022-3025.
[11]莫合拜提江·木拉买提,帕提曼·居马洪.阿奇霉素对支原体肺炎患儿心肌损伤的影响[J].中国药业,2016,25(10):41-43.
[12]郭辉,葛亮.炎琥宁联合阿奇霉素对支原体肺炎患儿炎性因子及免疫功能的影响[J].海南医学院学报,2017,23(20):2815-2817.
[13]杜赢,牛焕红,温慧,等.甘利欣联合阿奇霉素治疗支原体肺炎伴肝功能损害患儿的效果及对血清炎症因子、KL-6及NF-κB水平的影响[J].现代生物医学进展,2016,16(32):6348-6352.
[14]甘沛旋.阿奇霉素不同疗程在治疗小儿肺炎支原体肺炎中的临床效果观察[J].中国卫生标准管理,2018,9(7):82-84.
[15]王素霞,王静,任常军,等.阿奇霉素序贯疗法治疗小儿支原体肺炎的疗效和安全性分析[J].中国生化药物杂志,2014,34(5):133-134,138.
[2]陈会新,宋爱丽,肖永红.痰热清联合阿奇霉素治疗支原体肺炎疗效观察[J].临床肺科杂志,2014,19(2):359-361.
[3]王文雅,张秀敏,杜会双,等.阿奇霉素对支原体肺炎患儿血清IgA、IgG、IgM水平及T淋巴细胞亚群的影响[J].蚌埠医学院学报,2016,41(2):175-177.
[4]王宋青,施益农.热毒宁联合阿奇霉素对支原体肺炎患儿炎性因子及临床疗效的影响[J].广西医学,2016,38(8):1078-1080.
[5]陈跃宣,马洪梅.热毒宁联合阿奇霉素对支原体肺炎患儿抗炎、促炎因子及免疫功能的影响[J].海南医学院学报,2014,20(12):1702-1704.
[6]朴峻.痰热清注射液联合阿奇霉素对支原体肺炎患者肺功能、血清及痰液炎症介质的影响研究[J].世界中西医结合杂志,2016,11(3):388-391.
[7]夏玉平,方圆.孟鲁司特钠联合阿奇霉素对支原体肺炎儿童免疫功能及肺功能的影响[J].海南医学院学报,2016,22(18):2115-2117,2121.
[8]梁静仪,卢绍佳,姚春松,等.阿奇霉素对支原体肺炎患儿血清IL-2、sIL-2R及IL-17水平的影响[J].国际检验医学杂志,2014,35(8):956-957.
[9]谭义林,叶池林.布地奈德雾化吸入联合阿奇霉素对支原体肺炎患儿肺功能及血清炎症因子、免疫功能的影响[J].海南医学院学报,2016,22(22):2782-2784.
[10]宋海燕,王彬.红霉素与阿奇霉素治疗支原体肺炎临床效果比较[J].中国基层医药,2016,23(19):3022-3025.
[11]莫合拜提江·木拉买提,帕提曼·居马洪.阿奇霉素对支原体肺炎患儿心肌损伤的影响[J].中国药业,2016,25(10):41-43.
[12]郭辉,葛亮.炎琥宁联合阿奇霉素对支原体肺炎患儿炎性因子及免疫功能的影响[J].海南医学院学报,2017,23(20):2815-2817.
[13]杜赢,牛焕红,温慧,等.甘利欣联合阿奇霉素治疗支原体肺炎伴肝功能损害患儿的效果及对血清炎症因子、KL-6及NF-κB水平的影响[J].现代生物医学进展,2016,16(32):6348-6352.
[14]甘沛旋.阿奇霉素不同疗程在治疗小儿肺炎支原体肺炎中的临床效果观察[J].中国卫生标准管理,2018,9(7):82-84.
[15]王素霞,王静,任常军,等.阿奇霉素序贯疗法治疗小儿支原体肺炎的疗效和安全性分析[J].中国生化药物杂志,2014,34(5):133-134,138.